Affimed is a biotechnology business based in the US. Affimed shares (AFMD) are listed on the NASDAQ and all prices are listed in US Dollars. Affimed employs 219 staff and has a trailing 12-month revenue of around $34.1 million.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $0.49 |
|---|---|
| 52-week range | $0.45 - $2.55 |
| 50-day moving average | $0.56 |
| 200-day moving average | $0.87 |
| Wall St. target price | $5.96 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.78 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.486 from 2023-09-20
| 1 week (2023-09-14) | -4.14% |
|---|---|
| 1 month (2023-08-22) | -6.00% |
| 3 months (2023-06-22) | -28.53% |
| 6 months (2023-03-22) | -35.20% |
| 1 year (2022-09-22) | -76.06% |
|---|---|
| 2 years (2021-09-22) | -92.33% |
| 3 years (2020-09-22) | 3.5 |
| 5 years (2018-09-21) | 4.375 |
| Revenue TTM | $34.1 million |
|---|---|
| Gross profit TTM | $41.8 million |
| Return on assets TTM | -34.45% |
| Return on equity TTM | -76.31% |
| Profit margin | 0% |
| Book value | $0.66 |
| Market Capitalization | $71.7 million |
TTM: trailing 12 months
We're not expecting Affimed to pay a dividend over the next 12 months.
Over the last 12 months, Affimed's shares have ranged in value from as little as $0.4508 up to $2.55. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Affimed's is 2.1062. This would suggest that Affimed's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Affimed N. V. , a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers.
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.